Stockscreener 앱 받기
458.49
0.29%
-1.32
시간 외 거래:
457.50
-0.99
-0.22%
Vertex Pharmaceuticals Inc 주식(VRTX)의 최신 뉴스
Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
Is Vertex Pharmaceuticals Incorporated a good long term investmentMarket-leading growth rates - Autocar Professional
What drives Vertex Pharmaceuticals Incorporated stock priceFree Stock Selection - jammulinksnews.com
What analysts say about Vertex Pharmaceuticals Incorporated stockAccelerated wealth expansion - Jammu Links News
Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance
England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com
Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive
Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com
EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey
Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter
Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance
Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE
NICE backs Vertex's cystic fibrosis triple combo Alyftrek - FirstWord Pharma
Vertex Pharmaceuticals (VRTX) Receives a Buy from J.P. Morgan - The Globe and Mail
New cystic fibrosis triple from Vertex backed for NHS use - pharmaphorum
Vertex Pharmaceuticals and NHS England Reach Agreement to Provide Alyftrek for Cystic Fibrosis Treatment - geneonline.com
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - BioSpace
Vertex Pharmaceuticals' ALYFTREK® Approval: A Catalyst for EU Dominance and Revenue Growth? - AInvest
(Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX - Business Wire
Vertex Pharmaceuticals: A Steady Hand in a Volatile Market - AInvest
Vertex Pharmaceuticals Leads Biotech Stocks with 16%+ YTD Increase - AInvest
Why Vertex Pharmaceuticals Continues To Outperfrom (NASDAQ:VRTX) - Seeking Alpha
Small Fiber Neuropathy Market Growth Projections 2023-2032: DelveInsight Analysis | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark Pharma, Regency - Barchart.com
Regulatory tracker: Vertex, NHS England reach reimbursement deal for CF drug Alyftrek - Fierce Pharma
Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval - PMLiVE
Vertex Pharmaceuticals Q2 2025 Earnings: A Catalyst for Dominance in Rare Disease Therapeutics - AInvest
Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Business Wire
Cystic Fibrosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma - Barchart.com
RBC Capital Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)? - Insider Monkey
FDA Approves Suzetrigine by Vertex Pharmaceuticals for Acute Pain Relief in Adults - geneonline.com
Vertex Pharmaceuticals to Announce Q2 2025 Earnings on August 4th - AInvest
China Universal Asset Management Co. Ltd. Decreases Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY - Yahoo Finance
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek - Nasdaq
Vertex Pharma’s New Cystic Fibrosis Drug Granted Approval By EU - Stocktwits
, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock? - Yahoo Finance
H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug - Yahoo Finance
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
Vertex Pharmaceuticals Presents “Unprecedented” Data for T1D Cell Therapy Zimislecel, Shows Durable Benefit - Insider Monkey
Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain - BioSpace
Vertex posts additional trial data for type 1 diabetes therapy - Seeking Alpha
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake - Yahoo Finance
10 Biotech Stocks Screaming a Buy - Insider Monkey
Vertex Pharmaceuticals (VRTX) Soared as Investors Back Strategic Initiatives - Insider Monkey
0.55%
0.00%
자본화:
|
볼륨(24시간):